Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wataru Okamoto

Showing results (61-70 of 96) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2024
Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II TrialAkihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto, et al.
Cancer Medicine|March 13, 2024
Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinomaTakahiro Kinami, Shinsuke Uchikawa, Tomokazu Kawaoka, et al.
Internal Medicine (Tokyo, Japan)|November 3, 2022
Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular CarcinomaYumi Kosaka, Tomokazu Kawaoka, Masanari Kosaka, et al.
Journal of Gastroenterology and Hepatology|July 21, 2023
Correlation between serum pro-inflammatory cytokine levels and the prognosis of the patients with acute liver failureSerami Murakami, Takuro Uchida, Michio Imamura, et al.
International Journal of Clinical Oncology|January 19, 2011
High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatinYasuhiro Kidera, Taroh Satoh, Shinya Ueda, et al.
BMC Gastroenterology|August 1, 2021
Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year studyYuko Nagaoki, Hideyuki Hyogo, Yuwa Ando, et al.
Hepatology International|April 26, 2023
Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failureSerami Murakami, Michio Imamura, Takuro Uchida, et al.
Liver Cancer|August 21, 2023
Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular CarcinomaYuwa Ando, Tomokazu Kawaoka, Masanari Kosaka, et al.
Cancers|August 27, 2021
Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World PracticeYuwa Ando, Tomokazu Kawaoka, Masanari Kosaka, et al.
Cancers|May 16, 2023
Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-FetoproteinTakahiro Kinami, Kei Amioka, Tomokazu Kawaoka, et al.
Pageof 10

Showing results (61-70 of 96) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2024
Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II TrialAkihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto, et al.
Cancer Medicine|March 13, 2024
Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinomaTakahiro Kinami, Shinsuke Uchikawa, Tomokazu Kawaoka, et al.
Internal Medicine (Tokyo, Japan)|November 3, 2022
Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular CarcinomaYumi Kosaka, Tomokazu Kawaoka, Masanari Kosaka, et al.
Journal of Gastroenterology and Hepatology|July 21, 2023
Correlation between serum pro-inflammatory cytokine levels and the prognosis of the patients with acute liver failureSerami Murakami, Takuro Uchida, Michio Imamura, et al.
International Journal of Clinical Oncology|January 19, 2011
High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatinYasuhiro Kidera, Taroh Satoh, Shinya Ueda, et al.
BMC Gastroenterology|August 1, 2021
Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year studyYuko Nagaoki, Hideyuki Hyogo, Yuwa Ando, et al.
Hepatology International|April 26, 2023
Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failureSerami Murakami, Michio Imamura, Takuro Uchida, et al.
Liver Cancer|August 21, 2023
Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular CarcinomaYuwa Ando, Tomokazu Kawaoka, Masanari Kosaka, et al.
Cancers|August 27, 2021
Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World PracticeYuwa Ando, Tomokazu Kawaoka, Masanari Kosaka, et al.
Cancers|May 16, 2023
Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-FetoproteinTakahiro Kinami, Kei Amioka, Tomokazu Kawaoka, et al.
Pageof 10